Sangamo Therapeutics (SGMO) Free Cash Flow (2016 - 2025)
Historic Free Cash Flow for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$28.5 million.
- Sangamo Therapeutics' Free Cash Flow fell 34133.69% to -$28.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$76.1 million, marking a year-over-year increase of 3515.24%. This contributed to the annual value of -$67.4 million for FY2024, which is 7259.89% up from last year.
- According to the latest figures from Q3 2025, Sangamo Therapeutics' Free Cash Flow is -$28.5 million, which was down 34133.69% from -$18.0 million recorded in Q2 2025.
- In the past 5 years, Sangamo Therapeutics' Free Cash Flow ranged from a high of $11.8 million in Q3 2024 and a low of -$76.5 million during Q1 2021
- Moreover, its 5-year median value for Free Cash Flow was -$55.6 million (2021), whereas its average is -$46.7 million.
- In the last 5 years, Sangamo Therapeutics' Free Cash Flow tumbled by 56905.85% in 2021 and then surged by 12358.85% in 2024.
- Over the past 5 years, Sangamo Therapeutics' Free Cash Flow (Quarter) stood at -$55.6 million in 2021, then decreased by 16.11% to -$64.5 million in 2022, then increased by 17.53% to -$53.2 million in 2023, then surged by 93.93% to -$3.2 million in 2024, then plummeted by 782.16% to -$28.5 million in 2025.
- Its Free Cash Flow stands at -$28.5 million for Q3 2025, versus -$18.0 million for Q2 2025 and -$26.4 million for Q1 2025.